Skip to main content

Table 1 Mixed-ANOVA of P300 variables for SCA2 patients, preclinical carriers and healthy controls

From: Insights into cognitive decline in spinocerebellar Ataxia type 2: a P300 event-related brain potential study

ERP

Variable

SCA2 patients

Preclinical carriers

Healthy controls

Mixed-ANOVA

Group

Site

Group x Site

Visual

Latency

      

Cz

462.80 ± 7.40***/¶¶

421.34 ± 9.06*

384.68 ± 7.08

F = 53.73

F = 0.12

F = 0.10

Pz

463.41 ± 7.40***/¶¶

420.46 ± 9.92ns

390.54 ± 8.10

p < 0.0001

p > 0.05

p > 0.05

Amplitude

      

Cz

9.23 ± 1.12**

11.63 ± 1.41ns

15.28 ± 1.10

F = 14.00

F = 0.20

F = 0.06

Pz

9.03 ± 1.15**

11.44 ± 1.43ns

14.39 ± 1.09

p < 0.0001

p > 0.05

p > 0.05

Auditory

Latency

 

Cz

437.91 ± 8.88***/¶¶

380.66 ± 10.88ns

358.05 ± 9.64

F = 41.18

F = 1.09

F = 0.61

Pz

438.21 ± 9.79***

401.67 ± 11.79*

360.94 ± 10.76

p < 0.0001

p > 0.05

p > 0.05

Amplitude

 

Cz

9.47 ± 1.25*

12.63 ± 1.51ns

16.99 ± 1.29

F = 9.47

F = 0.263

F = 0.03

 

Pz

9.48 ± 1.11*

11.48 ± 1.33ns

15.50 ± 1.22

p < 0.0001

p > 0.05

p > 0.05

  1. Asterisks denote the statistical differences between SCA2 patients or preclinical carriers and controls (*:p < 0.05; **:p < 0.005; ***:p < 0.0005). Pilcrow denote the statistical differences between SCA2 patients and preclinical carriers (¶¶: p < 0.005)